Coronavirus disease 2019

Denise Kato

Co-Founder

 

At Traveling Tarts, the best luxury baking experiences in Los Angeles are as seamless as they are sweet…and that’s thanks to Denise Kato, our behind-the-scenes magic maker.

Denise is not only co-founder of Traveling Tarts. She’s the steady hand behind every event. From our interactive pie and tart baking parties to corporate dessert workshops and private Encino kitchen classes, she ensures that every detail is picture-perfect.

As our in-house professional photographer, Denise captures the joy of each hands-on baking experience. Her stunning photos showcase everything from flaky crusts and fresh berries to laughter-filled moments in our garden-to-table setup. These shots often end up in press, on our Instagram @traveling_tarts, and as cherished memories for our guests.

But Denise does more than just document the fun. She:

  • Helps plan and customize your take-home baking menu

  • Assists each guest through the tart or pie-making process

  • Oversees décor, design, and event flow

  • Helps manage logistics at off-site events, popup dessert activations, and VIP baking parties

Whether you’re attending one of our baking classes in Encino, hosting a team-building event, or planning a party for your closest friends, Denise is the reason every event feels elevated, elegant, and effortless.

As Kara always says:

“I couldn’t do this without Denise.”

We couldn’t agree more.


✨ Book Your Baking Experience

Ready to bake, sip, and create sweet memories?

📍 Book a private event or join a pop-up:
Visit www.travelingtarts.com
📧 Inquiries: hello@travelingtarts.com
📲 Follow us on Instagram: @traveling_tarts
🍓 Let’s get baking!

Coronavirus disease 2019

COVID-19 is a contagious disease caused by the coronavirus SARS-CoV-2. In January 2020, the disease spread worldwide, resulting in the COVID-19 pandemic.

The symptoms of COVID‑19 can vary but often include fever,[7] fatigue, cough, breathing difficulties, loss of smell, and loss of taste.[8][9][10] Symptoms may begin one to fourteen days after exposure to the virus. At least a third of people who are infected do not develop noticeable symptoms.[11][12] Of those who develop symptoms noticeable enough to be classified as patients, most (81%) develop mild to moderate symptoms (up to mild pneumonia), while 14% develop severe symptoms (dyspnea, hypoxia, or more than 50% lung involvement on imaging), and 5% develop critical symptoms (respiratory failure, shock, or multiorgan dysfunction).[13] Older people have a higher risk of developing severe symptoms. Some complications result in death. Some people continue to experience a range of effects (long COVID) for months or years after infection, and damage to organs has been observed.[14] Multi-year studies on the long-term effects are ongoing.[15]

COVID‑19 transmission occurs when infectious particles are breathed in or come into contact with the eyes, nose, or mouth. The risk is highest when people are in close proximity, but small airborne particles containing the virus can remain suspended in the air and travel over longer distances, particularly indoors. Transmission can also occur when people touch their eyes, nose, or mouth after touching surfaces or objects that have been contaminated by the virus. People remain contagious for up to 20 days and can spread the virus even if they do not develop symptoms.[16]

Testing methods for COVID-19 to detect the virus’s nucleic acid include real-time reverse transcription polymerase chain reaction (RT‑PCR),[17][18] transcription-mediated amplification,[17][18][19] and reverse transcription loop-mediated isothermal amplification (RT‑LAMP)[17][18] from a nasopharyngeal swab.[20]

Several COVID-19 vaccines have been approved and distributed in various countries, many of which have initiated mass vaccination campaigns. Other preventive measures include physical or social distancing, quarantining, ventilation of indoor spaces, use of face masks or coverings in public, covering coughs and sneezes, hand washing, and keeping unwashed hands away from the face. While drugs have been developed to inhibit the virus, the primary treatment is still symptomatic, managing the disease through supportive care, isolation, and experimental measures.